Conference Call and Webcast at 5:00 pm Eastern Time
THE WOODLANDS, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones.
“We are on track for submission around year-end of our new drug application for sotagliflozin for the treatment of heart failure in patients with type 2 diabetes,” said Lonnel Coats, Lexicon’s chief executive officer. “Momentum continues to build for the adoption of SGLT inhibitors into the first-line heart failure treatment regimen, as most recently evidenced by the new clinical practice guidelines issued in late August by the European Society of Cardiology (ESC). We believe that sotagliflozin’s unique mechanism of action as a dual SGLT1 and SGLT2 inhibitor offers differentiating advantages in this emerging market, with a particular opportunity in heart failure with preserved ejection fraction (HFpEF), and that a primary point of engagement will be with specialists treating patients who have been recently hospitalized for worsening heart failure, which was the cornerstone of our SOLOIST study. We are building our launch readiness team in preparation for potentially bringing sotagliflozin to patients suffering from heart failure and living with type 2 diabetes next year.”
Third Quarter Highlights
Sotagliflozin
- ESC issued new treatment guidelines adding SGLT inhibitors to the standard of care for the prevention and treatment of heart failure. Sotagliflozin was specifically recommended for the primary prevention of heart failure in type 2 diabetes patients with risk factors for its development and the treatment of heart failure in patients with type 2 diabetes, and was also noted in the guidelines in the context of worsening heart failure.
- Additional analyses of sotagliflozin data from the SOLOIST and SCORED Phase 3 clinical studies were presented at the ESC Congress 2021 highlighting the benefits seen in reduced heart failure hospitalizations, myocardial infarction and stroke.
LX9211
- Patient enrollment continued in two ongoing Phase 2 clinical studies of LX9211 for the treatment of diabetic peripheral neuropathic pain and the treatment of post-herpetic neuralgia. Results from these clinical studies are currently expected in the first half of 2022.
Corporate
- Craig B. Granowitz, M.D., Ph.D. joined Lexicon as senior vice president and chief medical officer, with a deep and successful history in cardiovascular medicine. Dr. Granowitz will lead the build-out of Lexicon’s medical affairs organization as the company prepares for the potential launch of sotagliflozin for the treatment of heart failure in patients with type 2 diabetes.
Third Quarter 2021 Financial Highlights
Revenues: Revenues for the three months ended September 30, 2021 were negligible as compared to $6.6 million for the corresponding period in 2020, primarily due to the absence of product revenues as a result of Lexicon’s sale of its XERMELO® product and related assets to TerSera Therapeutics LLC during the third quarter of 2020.
Research and Development (R&D) Expenses: Research and development expenses for the three months ended September 30, 2021 decreased to $15.7 million from $40.1 million for the corresponding period in 2020, primarily due to decreases in external clinical development costs related to sotagliflozin resulting from the completion of clinical studies.
Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the three months ended September 30, 2021 decreased to $7.3 million from $12.0 million for the corresponding period in 2020, primarily due to lower salaries and benefits costs as a result of reductions in personnel in September 2020 and lower marketing expenses, all primarily associated with the sale of XERMELO and related assets during the third quarter of 2020.
Net Loss: Net loss for the three months ended September 30, 2021 was $23.1 million, or $0.16 per share, as compared to net income of $82.6 million, or $0.71 per diluted share, in the corresponding period in 2020. The three months ended September 30, 2020 included a gain of $132.8 million from the sale of XERMELO and related assets to TerSera. For the three months ended September 30, 2021 and 2020, net income included non-cash, stock-based compensation expense of $2.7 million and $1.9 million, respectively.
Cash and Investments: As of September 30, 2021, Lexicon had $120.9 million in cash and investments, as compared to $152.3 million as of December 31, 2020.
Conference Call and Webcast Information
Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is 888-645-5785 (U.S./Canada) or 970-300-1531 (international). The conference ID for all callers is 8564549. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
About the SOLOIST and SCORED Studies
SOLOIST was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.
SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m2 of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.
Both SOLOIST and SCORED achieved their respective primary endpoints. Results from both studies were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.”
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
| Lexicon Pharmaceuticals, Inc. | |||||||||||||||||
| Selected Financial Data | |||||||||||||||||
| Consolidated Statements of Operations Data | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (In thousands, except per share data) | 2021 | 2020 | 2021 | 2020 | |||||||||||||
| (Unaudited) | (Unaudited) | ||||||||||||||||
| Revenues: | |||||||||||||||||
| Net product revenue | $ | – | $ | 6,542 | $ | – | $ | 23,404 | |||||||||
| Collaborative agreements | – | – | – | 33 | |||||||||||||
| Royalties and other revenue | 23 | 92 | 284 | 359 | |||||||||||||
| Total revenues | 23 | 6,634 | 284 | 23,796 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Cost of sales (including finite-lived intangible | |||||||||||||||||
| asset amortization) | – | 633 | – | 1,929 | |||||||||||||
| Research and development, including stock-based | |||||||||||||||||
| compensation of $1,138, $1,029, $3,608 and $5,154, respectively | 15,682 | 40,147 | 38,548 | 152,629 | |||||||||||||
| Selling, general and administrative, including stock-based | |||||||||||||||||
| compensation of $1,574, $875, $4,741 and $5,440, respectively | 7,303 | 11,997 | 23,496 | 40,798 | |||||||||||||
| Impairment loss on buildings | – | – | – | 1,600 | |||||||||||||
| Total operating expenses | 22,985 | 52,777 | 62,044 | 196,956 | |||||||||||||
| Other operating income: | |||||||||||||||||
| Gain on sale of XERMELO | – | 132,818 | – | 132,818 | |||||||||||||
| Income (loss) from operations | (22,962 | ) | 86,675 | (61,760 | ) | (40,342 | ) | ||||||||||
| Loss on debt extinguishments, net | – | (255 | ) | – | (255 | ) | |||||||||||
| Interest expense | (171 | ) | (4,118 | ) | (507 | ) | (14,374 | ) | |||||||||
| Interest and other income, net | 11 | 301 | 120 | 1,892 | |||||||||||||
| Net income (loss) | $ | (23,122 | ) | $ | 82,603 | $ | (62,147 | ) | $ | (53,079 | ) | ||||||
| Net income (loss) per common share, basic | $ | (0.16 | ) | $ | 0.77 | $ | (0.43 | ) | $ | (0.50 | ) | ||||||
| Net income (loss) per common share, diluted | $ | (0.16 | ) | $ | 0.71 | $ | (0.43 | ) | $ | (0.50 | ) | ||||||
| Shares used in computing net income (loss) per common share, basic | 145,820 | 107,309 | 144,558 | 106,974 | |||||||||||||
| Shares used in computing net income (loss) per common share, diluted | 145,820 | 117,552 | 144,558 | 106,974 | |||||||||||||
| As of | As of | ||||||||||||||||
| Consolidated Balance Sheet Data | Sept. 30, 2021 | Dec. 31, 2020 | |||||||||||||||
| (In thousands) | (Unaudited) | ||||||||||||||||
| Cash and investments | $ | 120,918 | $ | 152,275 | |||||||||||||
| Property and equipment, net | 1,311 | 295 | |||||||||||||||
| Goodwill | 44,543 | 44,543 | |||||||||||||||
| Total assets | 172,330 | 203,788 | |||||||||||||||
| Current debt | 11,693 | 11,646 | |||||||||||||||
| Accumulated deficit | (1,462,165 | ) | (1,400,018 | ) | |||||||||||||
| Total stockholders’ equity | 136,603 | 156,371 | |||||||||||||||
For Inquiries:
Chas Schultz
Executive Director, Corporate Communications and Investor Relations
Lexicon Pharmaceuticals
(281) 863-3421
cschultz@lexpharma.com
